Close
Explore more Centres, Projects and Groups
Home
Welcome Banner
Praziquantel in Preschool Children (PIP trial)

Praziquantel in Preschool Children (PIP trial)

The Praziquantel in Preschoolers trial (PIP) aims to find the right treatment dose of praziquantel for preschool children living with intestinal schistosomiasis in Uganda.

Bottom Content
About us

Intestinal schistosomiasis is a complex parasitic disease that affects millions of children in worldwide. With only one drug to treat it (praziquantel), there is still no optimal dosing for children under 5 years of age.

About
Praziquantel in Preschool Children (PIP trial) 2 columns
Praziquantel in Preschool Children (PIP trial) about
Paragraph

Intestinal schistosomiasis is a complex parasitic disease that affects millions of children worldwide. With only one drug to treat it (praziquantel), there is still no optimal dosing for children under 5 years of age.

The PIP trial (Praziquantel in Preschoolers) is a five year randomised controlled trial investigating different doses and treatment intervals of praziquantel given to children under five years of age. It will also explore the role of intestinal pathology on the pharmacokinetics and pharmacodynamics of praziquantel and its role in drug efficacy.

Collaborating partners

Center for international health research lifespan
MRC Uganda
Uganda logo
University of Liverpool
Brown University-Center for International Health Research  LSHTM-MRC Unit Vector Control Division
Uganda Ministry of Health
University of Liverpool

Funder

NIH

National Institutes of Health (NIH)

Who we are

The PIP Trial is funded by the National Institutes of Health in the USA. It brings together LSHTM, Brown University, the LSHTM MRC unit in Uganda and the Vector Control Division from the Ministry of Health in Uganda.

Profiles
Principal Investigators

Jennifer Friedman

Uganda Principal Investigator

Patrice Mawa

Edridah Muheki

Co-investigators

Narcis Kabatereine

Alison Elliott

Publications
Scientific Papers
Population Pharmacokinetics and Pharmacodynamics of Praziquantel in Ugandan Children with Intestinal Schistosomiasis: Higher Dosages Are Required for Maximal Efficacy
Bustinduy, Amaya; Waterhouse, David; Sousa-Figueiredo, Jose C; Roberts, Stephen A.; Atuhaire, Aaron; Van Dam, Govert J.; Corstjens, Paul L. A. M.; Scott, Janet T.; Stanton, Michelle C.; Kabatereine, Narcis B.; Ward, Stephen; Hope, William W.; Stothard, J.Russell
2016
MBio. ISSN 2150-7511 DOI: https://doi.org/10.1128/mBio.00227-16
Expanding Praziquantel (PZQ) Access beyond Mass Drug Administration Programs: Paving a Way Forward for a Pediatric PZQ Formulation for Schistosomiasis.
Bustinduy, AL; Friedman, JF; Kjetland, EF; Ezeamama, AE; Kabatereine, NB; Stothard, JR; King, CH
2016
PLoS neglected tropical diseases, 10 (9). e0004946. ISSN 1935-2727 DOI: https://doi.org/10.1371/journal.pntd.0004946 Export
Paediatric and maternal schistosomiasis: shifting the paradigms
Bustinduy, AL; Stothard, JR; Friedman, JF
2017
British medical bulletin, 123 (1). pp. 115-125. ISSN 0007-1420 DOI: https://doi.org/10.1093/bmb/ldx028
One hundred years of neglect in paediatric schistosomiasis
Bustinduy, AL; Wright, S; Joekes, EC; Kabatereine, NB; Reinhard-Rupp, J; King, CH; Stothard, JR
2017
Parasitology. pp. 1-11. ISSN 0031-1820 DOI: https://doi.org/10.1017/S0031182017000014